SP-2577 and ABL2 Inhibitor Combination for Ewing Sarcoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for Ewing's Sarcoma, including surgery, chemotherapy, and radiotherapy, have limited effectiveness, and recent LSD1 inhibitors like SP-2577 show little antitumoral activity, necessitating a more potent treatment strategy that targets multiple pathways to overcome resistance mechanisms.
Innovation Solution
Combining SP-2577, a potent LSD1 inhibitor, with drugs targeting the ABL2 pathway, such as Ruxolitinib, Dasatinib, Nilotinib, Imatinib, and Bosutinib, to enhance cytotoxicity and synergistic effects, identified through CRISPR screening, which downregulates survival genes and increases treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SP-2577 (LSD1 inhibitor) is used as monotherapy, then the treatment targets a specific molecular pathway, but the antitumoral activity is insufficient and resistance mechanisms develop
Solution Approach 1:
The patent combines SP-2577 (LSD1 inhibitor) with ABL2 pathway inhibitors (dasatinib, imatinib, nilotinib, bosutinib, ruxolitinib) to create a combination therapy that targets multiple molecular pathways simultaneously. This merging of therapeutic agents addresses the insufficiency of monotherapy by attacking the tumor through multiple mechanisms, thereby improving therapeutic efficacy and reducing resistance development.
2Reliability
If combination therapy with multiple drugs is used, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent employs ABL2 pathway inhibitors that serve multiple functions: they inhibit ABL2 kinase activity, interfere with EWS-FLI1 fusion protein function, and sensitize tumor cells to LSD1 inhibitor therapy. This multi-functionality allows a single class of drugs to address multiple therapeutic needs, thereby improving efficacy while managing treatment complexity.
3Reliability
If high doses of single agent are used, then cytotoxicity may be maximized, but toxicity and side effects increase
Solution Approach 1:
The patent uses low doses of both SP-2577 and ABL2 inhibitors in combination, where each agent at a sub-maximal dose produces moderate cytotoxicity. The combined effect of these partial actions achieves synergistic cytotoxicity that exceeds the sum of individual effects, maximizing tumor cell death while keeping individual drug doses low enough to minimize toxicity and side effects.
Data Source
AI summary
The present disclosure includes compounds and methods for treating a subject having a cancer, in particular. Ewing's Sarcoma. A method of treating Ewing's Sarcoma in a subject may comprise the steps of administering to the subject a therapeutically effective amount of a first pharmaceutical composition comprising SP-2577 and administering to the subject a therapeutically effective amount of a second pharmaceutical composition selected from the group consisting of Ruxolitinib, Dasatinib, Nilotinib, Imatinib, Bosutinib, and a drug targeting ABL2 pathway. The drug targeting ABL2 pathway may be an ABL2 knockdown drug, i.e., an ABL2 inhibitor.